Literature DB >> 10881743

Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas.

J Reifenberger1, M Wolter, J Boström, R Büschges, K W Schulte, M Megahed, T Ruzicka, G Reifenberger.   

Abstract

Malignant melanomas frequently show loss of alleles on the long arm of chromosome 10. The PTEN (MMAC1) gene has been identified as a tumour suppressor gene at 10q23.3 that is mutated in various types of advanced human cancers. We have investigated a series of 40 sporadic melanomas from 37 patients (15 primary cutaneous melanomas and 25 melanoma metastases) for allelic losses on chromosome 10, as well as for deletion and mutation of the PTEN gene. Microsatellite analysis revealed loss of heterozygosity at loci located on 10q in tumours from 15 of 34 patients investigated (44%). Somatic PTEN mutations were identified in melanomas from 4 of 37 patients (11%), all of whom had metastatic disease. In two of these patients, the tumours had additionally lost one PTEN allele, indicating complete loss of wild-type PTEN in the tumour cells. Our findings corroborate that loss of heterozygosity on chromosome 10 is a frequent aberration in malignant melanomas and implicate PTEN as a tumour suppressor gene inactivated by somatic mutation in a fraction of these tumours.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10881743     DOI: 10.1007/s004280050477

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  22 in total

Review 1.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 2.  Cutting edge in medical management of cutaneous oncology.

Authors:  Kim Chong; Adil Daud; Susana Ortiz-Urda; Sarah T Arron
Journal:  Semin Cutan Med Surg       Date:  2012-06

Review 3.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

4.  New horizons in melanoma treatment: targeting molecular pathways.

Authors:  Christopher W M Soon; Alain P Algazi; Edward N Cha; Adil I Daud
Journal:  Ochsner J       Date:  2010

5.  Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation.

Authors:  Vallian Sadeq; Nassiri Isar; Tavassoli Manoochehr
Journal:  Med Oncol       Date:  2010-03-17       Impact factor: 3.064

6.  Negative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing Field.

Authors:  Fernanda Ledda; Gustavo Paratcha
Journal:  Biomark Insights       Date:  2007-02-14

Review 7.  The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-28       Impact factor: 4.693

Review 8.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

Review 9.  Genetic pathways to melanoma tumorigenesis.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

10.  [Molecular heterogeneity of malignant melanomas].

Authors:  K Glatz
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.